Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
  • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
  • A61K9/0058—Chewing gums
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
  • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives

Definitions

• the present invention relates to a doxylamine resinate complex formed between doxylamine and a synthetic weakly acidic cation exchange resin, a process for preparation of the same and its use as a medicament for the treatment of occasional insomnia.
• the invention also relates to pharmaceutical formulations comprising said doxylamine resinate complex, such as oral pharmaceutical formulations.
• Doxylamine is an ethanolamine-based antihistamine used in the management of insomnia and, in combination with antitussives and decongestants, in the relief of cough and cold symptoms. It is also used in combination with the analgesics paracetamol (acetaminophen) and codeine as an analgesic/calmative preparation, and is prescribed in combination with vitamin B 6 (pyridoxine) to prevent morning sickness in pregnant women.
• Doxylamine whose chemical name is (flS)-A/,A/-dimethyl-2-(1 -phenyl-1 -(pyridin-2- yl)ethoxy)ethanamine, has the following formula:
• Doxylamine is available in the market as a physiologically acceptable salt, particularly as a succinate.
• Doxylamine succinate has high hygroscopicity (deliquescent) which can result in a need for special manufacturing conditions or a difficulty to keep the properties of the dosage forms for a long time.
• Doxylamine succinate also suffers from the disadvantage of having incompatibility with some pharmaceutical excipients such as aspartame, which results in degradation and an increase of impurities in pharmaceutical preparation containing the same.
• Doxylamine succinate has an inherently bitter taste, and this constitutes a further disadvantage in particular when formulating certain types of oral preparations. In this sense, it is well known that patients may not complete a necessary course of medicine if they are prescribed an oral presentation which is particularly unpleasant to taste.
• bitter taste may be masked by the use of sweetening and/or flavouring agents or lipidic coatings although these are not satisfactory and an unpleasant after-taste may still remain in the mouth.
• oral formulations of doxylamine succinate are not at the present time entirely satisfactory.
• Ion exchange resins have been also disclosed as means for providing oral formulations with controlled or sustained release properties.
• WO 92/1 1038 discloses oral pharmaceutical preparations which comprise a pharmacologically-active polyamine drug bound to a cation-exchange resin to provide a drug-resin complex having a drug content greater than one equivalent of amine per equivalent of cation-exchange capacity which provides a controllable release of drug under conditions encountered in the gastrointestinal tract (immediate release of the polyamine drug bound in excess of one equivalent and a slower release of the remaining polyamine drug).
• the cation exchange resin used, Amberlite IRP 69 is a strong acid cation resin, derived from a sulfonated copolymer of styrene and divinylbenzene.
• the problem to be solved by the present invention is to provide a new drugable form of doxylamine which overcomes at least part of the disadvantages above mentioned.
• a new drugable form of doxylamine that can also be more convenient for use in a pharmaceutical formulation for faster or immediate release in an aqueous environment.
• One of the objects of the present invention is thus improving the release rate of doxylamine by providing new drugable forms of doxylamine having a quick delivery of doxylamine and resulting in a faster therapeutic onset.
• Another object of the present invention is the provision of new drugable forms of doxylamine having less hygroscopicity.
• the inventors have now found that it is possible to form a complex between doxylamine and a synthetic weakly acidic cation exchange resin providing a doxylamine resinate complex.
• the doxylamine resinate complex surprisingly presents a decreased hygroscopicity and an improved stability compared to the doxylamine succinate when is combined with some pharmaceutical acceptable excipients which results therefore, in a more stable drugable form of doxylamine.
• the resinate complex presents the advantage that it is much easier to administer orally since it is substantially free of the bitter taste associated with doxylamine succinate.
• the present invention relates to a doxylamine resinate complex, hereinafter referred to as the resinate complex of the invention, comprising doxylamine bound to a weakly acidic synthetic cation exchange resin.
• any weakly acidic synthetic cation exchange resin presenting carboxylic groups can be used to prepare the doxylamine resinate complex as long as it is pharmaceutically acceptable.
• Preferred weakly acidic synthetic cation exchange resins are polyacrylic copolymers and copolymers of methacrylic acid and divinylbenzene, the latter being more preferred, which can be either synthesized according to well known methods in the art or are commercially available.
• resins suitable for use in the resinate complex of the invention are Amberlite IRP64, Amberlite IRP88, Amberlite IRC86, and Amberlite IRC76 (Rohm and Haas).
• the Amberlite IRP64 hereinafter also referred to as polacrilex, is a preferred resin which presents the following chemical structure:
• the doxylamine content present in the resinate complex of the invention has been determined and is comprised between 10% by weight and 55% by weight, preferably between 15% by weight and 30% by weight, in respect of the total weight of the doxylamine resinate complex.
• the doxylamine complexation efficiency has been determined to be comprised between 80 - 95 %.
• the present invention provides in another aspect a process for the preparation of the doxylamine resinate complex of the invention.
• the process comprises contacting a weakly acidic synthetic cation exchange resin as above disclosed with doxylamine or with a pharmaceutically acceptable salt thereof.
• the binding may be performed according to known methods for the skilled person, for example as a batch or column process.
• the resinate complex is prepared by a batch process which comprises the steps of contacting the resin previously hydrated in an aqueous buffer solution with doxylamine or a pharmaceutically acceptable salt of doxylamine. The resulting suspension is stirred and maintained until complexation equilibrium is achieved.
• the resinate complex formed is then filtrated and washed with distilled water to assure elimination of unbound doxylamine and optionally dried, to obtain a fine white powder.
• the process can be carried out at a range temperature of 25 to 60 e C. Preferably the temperature is comprised between 40-50 e C.
• the binding step is carried out at a pH value at which the carboxylic groups of the weakly acidic synthetic cation exchange resin are in ionic form and the doxylamine is protonated.
• the pH value can thus be easily determined by the skilled person in each case. Typically the pH value is equal or higher than 4.
• the mobile exchangeable cation in the resin can be a hydrogen ion, (H + ) or a cation such as for instance sodium (Na + ), potassium (K + ), or ammonium (NH 4 + ).
• the doxylamine is used in the form of the pharmaceutically acceptable salt of doxylamine, more particularly as doxylamine succinate.
• doxylamine succinate the weight ratio used of doxylamine succinate to the weakly acidic synthetic cation exchange resin ranges from 1 :1 to 1 :5.
• the release of doxylamine from the doxylamine resinate complex added to a release media was determined according to the USP XXIII Paddle Method using a USP Dissolution Tests apparatus 2 (paddles) at 37 e C and 50 rpm in 900 mL of 0.1 N HCI during 30 minutes. Dissolution profiles of doxylamine from doxylamine resinate complex showed a fast release, e.g. > 85% of doxylamine was released under the above conditions.
• the release of doxylamine from the doxylamine resinate complex is similar to the release of doxylamine succinate which means the resinate complex provides an immediate release of doxylamine.
• This fast release is especially desirable to obtain immediate release formulations, for example in oral dispersible tablet (ODT).
• ODT oral dispersible tablet
• These solid dosage forms are forms that disintegrate and dissolve in the mouth without water within 60 seconds or less.
• the drug release rate of a doxylamine resinate complex when compared to that of the doxylamine succinate alone can be used as an indication of whether a drug formulation with an even faster release profile could be made, and therefore, can be used to prepare a beneficial pharmaceutical product (see Example 8).
• particle size distribution of doxylamine resinate complex has been determined by Laser Diffraction Analyzer (Malvern Mastersizer 2000) by wet measurement mode.
• particle size of doxylamine resinate complex defined as volume weighted mean D[4,3] is comprised between 20 ⁇ and 300 ⁇ , preferably between 30 ⁇ and 100 ⁇ .
• the resinate complex of the invention is used in the preparation of pharmaceutical compositions. It is a more stable drugable form of doxylamine than doxylamine succinate, which is the available physiologically acceptable salt of doxylamine in the market.
• the resinate complex of the invention is less hygroscopic and more compatible with some common pharmaceutical acceptable carriers, adjuvants or vehicles, generally referred also as excipients.
• excipients are magnesium stearate, stearic acid, povidone K90, lactose and aspartame.
• the invention provides a pharmaceutical composition comprising the resinate complex of the invention, hereinafter referred to as the composition of the invention.
• the composition of the invention further comprises at least one pharmaceutical acceptable excipient.
• a pharmaceutical composition according to the present invention may be in any form suitable for the application or administration to humans and/or animals, preferably humans including infants, children and adults, by any route of administration.
• the composition may be in any dosage form and can vary depending on the route of administration. Examples include, among others, solid forms like powders, tablets, pills, capsules, etc., or liquid forms such as drops, solutions, suspensions, emulsions etc., for oral or topical administration.
• the resinate complex of the invention is substantially free of bitter, unpalatable taste, and therefore it is particularly suitable for use in the preparation of pharmaceutical compositions for oral administration a route of administration which is generally preferred for the convenience of the patient.
• the fast dissolution profile of the doxylamine from the resinate complex of the invention as above stated makes it suitable for its use in oral immediate release pharmaceutical formulations.
• compositions according to the invention can be in form of orally administrable compositions containing one or more physiologically compatible excipients, in solid or liquid form.
• the compositions may take any convenient form, such as oral pharmaceutical dosage forms like tablets, capsules, lozenges, granules, powders which can be filled in sachets or stick pack, chewable tablets, oral dispersible tablets (ODT), or chewing gums.
• These compositions may contain conventional excipients such as binding agents, fillers, lubricants, and may also contain further excipients (additives) such as sweeteners, flavourings and preservatives.
• Preferred pharmaceutical compositions are oral dosage forms, more preferably chewable tablets, oral dispersible tablets (ODT) and powders filled in sachets. These pharmaceutical compositions are convenient dosage forms for most patients having difficulties in swallowing tablets, i.e. children and aged persons. In the following, percentages are by weight in respect of the total weight of the pharmaceutical composition, unless otherwise specifically stated.
• compositions of the invention comprise a doxylamine resinate complex as defined above in an amount comprised between 10 to 50 weight-%, preferably 10 to 40 weight-%, most preferably 10 to 30 weight-%.
• compositions of the invention may further contain fillers, disintegrants, binders, lubricants, sweeteners and flavours that can be any pharmacologically acceptable ingredients know in the art.
• the filler is preferably selected from sugar alcohols like mannitol, xylitol, isomalt, sorbitol, erythritol, sucrose, fructose, dextrose, threalose, and calcium phosphate, and is more preferably isomalt or mannitol and also fillers from the family of lactose.
• the pharmaceutical composition according to the invention comprises 30 to 80 weight-% of the filler/s, preferably 40 to 80 weight-%.
• the disintegrant is preferably selected from crosspovidone, sodium starch glycolate, croscarmellose sodium, polacrilin potassium, pregelatinized starch, low substituted hydroxypropyl cellulose (L-HPC) and mixtures thereof.
• the pharmaceutical composition according to the invention comprises 3 to 20 weight-% of the disintegrant/s, preferably 4 to 15 weight-%.
• the binder is preferably selected from microcrystalline cellulose, corn starch, polyethylene glycol, hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), polyvinylpyrrolidone, magnesium aluminium metasilicate, methyl cellulose and mixtures thereof.
• the pharmaceutical composition according to the invention comprises 5 to 50 weight-% of the binder/s, preferably 7 to 20 weight-%.
• the lubricant is preferably selected from sodium stearyl fumarate, magnesium stearate, calcium stearate, talc, hydrophilic fumed silica, glyceryl dibehenate, glycerol distearate, behenoyl-polyoxyl glyceride and mixtures thereof.
• the pharmaceutical composition according to the invention comprises 0.1 to 6 weight-% of the lubricant/s, preferably 1 to 5 weight-%.
• the sweeteners are preferably selected from aspartame, cyclamate, sucrose, sucralose, sodium saccharin and mixtures thereof and most preferably aspartame.
• the pharmaceutical composition according to the invention comprises 0.1 to 5 weight-% of the sweetener/s, preferably 0.5 to 4 weight-%.
• compositions of the invention comprise a doxylamine resinate complex as defined above and at least a filler.
• these pharmaceutical compositions comprises 10 to 50 weight-% of doxylamine resinate complex, preferably 10 to 40 weight-%, most preferably 10 to 30 weight-%.
• the quantity of filler used in the pharmaceutical composition according to the invention lies between 30-80 weight-%, preferably between 40-80 weight-%.
• compositions comprise 10 to 50 weight-% of doxylamine resinate complex, at least 30 to 80% of a filler, 3 to 20% of at least a disintegrant, 5 to 50% of at least a binder, 0.1 to 6 % of at least a lubricant, 0.1 to 5% of at least a sweetener and 0.1 to 5 % of at least a flavour.
• Moisture can affect flow and compaction of powders during manufacture of a final dosage form. Also storage and stability of a final dosage form, chewable or ODT tablet of doxylamine can be compromised.
• doxylamine succinate it is important to have a new drugable form of doxylamine to protect it from humidity in order to improve final stability of doxylamine pharmaceutical dosage forms.
• the new drugable form of doxylamine is less hygroscopic and more stable when it is combined with some common pharmaceutical acceptable excipients
• pharmaceutical dosage forms comprising the resinate complex of the invention can be advantageously manufactured having the packaging requirements simplified.
• the resinate complex of the invention is capable of masking the bitter taste associated with doxylamine succinate which is a further advantage in the manufacturing of oral pharmaceutical dosage forms, particularly the preferred pharmaceutical compositions of the present invention.
• the present invention provides a process for the preparation of the pharmaceutical composition of the invention.
• Said compositions may be prepared by conventional standard procedures known to those skilled in the art such as those described in the European or US Pharmacopoeias or similar reference texts.
• the preparation of tablets according to the invention can be achieved according to conventional tabletting techniques, for example dry granulation or wet granulation, and direct compression.
• the manufacturing of the ODT involves direct compression technology.
• the process for the preparation of the pharmaceutical compositions of the invention comprises the use of a doxylamine resinate complex as defined above in an amount comprised between 10 to 50 weight-%, preferably 10 to 40 weight-%, most preferably 10 to 30 weight-%.
• the process for the preparation of the pharmaceutical compositions of the invention comprises the use of a doxylamine resinate complex as defined above in an amount comprised between 10 to 50 weight- %, preferably 10 to 40 weight-%, most preferably 10 to 30 weight-% and at least a filler.
• the quantity of filler blended with doxylamine resinate complex in the pharmaceutical composition according to the invention lies between 30-80 weight-%, preferably between 40-80 weight-%.
• 10 - 50% of doxylamine resinate complex is blended with at least 30 - 80% of a filler, 3 - 20% of at least a disintegrant, 5 - 50% of at least a binder, 0.1 - 6 % of at least a lubricant, 0.1 - 5% of at least a sweetener and 0.1 - 5 % of at least a flavour. After the blending the blended product is compressed to achieve the tablets.
• the pharmaceutical composition is in form of a dosage form for the treatment of occasional insomnia comprising a therapeutically effective amount of doxylamine resinate complex.
• a therapeutically effective amount is to be understood as the amount necessary to achieve a benefice in a treated patient suffering from occasional insomnia.
• the therapeutically effective amount will depend on several factors such as weight and sex of the sufferer, the severity of the occasional insomnia, etc.
• the resinate complex of the invention will typically be administered once or more times a day with typical doses in the range of form 0.1 to 2.5 mg /kg/day.
• the invention provides the doxylamine resinate complex of the invention for use as a medicament.
• said medicament is for the use in the treatment of occasional insomnia.
• Example 5 the degree of the hygroscopicity of a resinate complex according to the invention (Sample 2) was compared with the hygroscopicity degree of doxylamine succinate (Sample 1 ). Both samples 1 and 2 were exposed to humidity conditions for 24 hours and the results from the % increase in mass are shown in the Table 2 of Example 5. It can be seen that in the case of sample 1 , sufficient water was absorbed to form a liquid, whereas in sample 2, the same appearance of solid state was observed after the experiment. According to the mentioned scale in Example 5, doxylamine succinate would be deliquescent, whereas doxylamine polacrilex complex would be considered as hygroscopic. Thus it can be concluded that the resinate complex of the invention presents a decreased hygroscopicity compared to the doxylamine succinate.
• Doxylamine succinate:aspartame (1 :1 ) (Table 7) showed some degradation of the doxylamine succinate component (see the presence of related substances 2, 3, 4 and 5) after 15 and 30 days at 40 e C/75%RH. It can be also observed after 15 and 30 days at 40 e C/75%RH a conversion of aspartame (appearance of substances 6 to 9) probably due to equilibrium between the zwitterionic form and the partially ionized forms. At the condition studied of 15 days or 30 days at 50 e C, doxylamine succinate:aspartame (1 :1 ) did not show major changes during the study.
• the invention provides the use of doxylamine resinate complex to increase the excipient compatibility of doxylamine.
• the excipient is selected from magnesium stearate, stearic acid, povidone K90, lactose and aspartame.
• the excipient is aspartame.
• the invention provides the use of doxylamine resinate complex to decrease hygroscopicity of doxylamine.
• the suspension was filtered through a centrifuge.
• the cake was washed with 10 L of distilled water and dried in a rotary drier at 60 e C.
• the complex Amberlite IRP64 - doxylamine is obtained as a fine white powder containing from 18.7 % of doxylamine free base.
• the doxylamine complexation efficiency obtained is 90.3 %.
• Example 2 Doxylamine - Polacrilex Oral Dispersible Tablet.
• the oral disintegrating tablets containing doxylamine - Amberlite IRP64 complex were prepared by direct compression technology.
• the doxylamine - Amberlite IRP64 complex was blended with mannitol, crosspovidone (or sodium starch glycolate), microcrystalline cellulose, sodium stearyl fumarate, aspartame and flavour.
• the blended product was compressed to achieve tablets with the following composition.
• Example 3 Doxylamine - Polacrilex Oral Dispersible Tablet.
• the oral disintegrating tablets containing doxylamine - Amberlite IRP64 complex were prepared by direct compression technology.
• the doxylamine - Amberlite IRP64 complex was blended with mannitol, crosspovidone (or sodium starch glycolate), citric acid monohydrate, sodium stearyl fumarate, iron (III) oxide, aspartame and flavour.
• the blended product was compressed to achieve tablets with the following composition.
• the chewable tablets containing Doxylamine - Amberlite IRP64 complex were prepared by direct compression technology.
• the doxylamine - Amberlite IRP64 complex was blended with soluble isomalt, polyethylene glycol, sodium stearyl fumarate, aspartame and flavours.
• the blended product is compressed to achieve tablets
• the blended product was compressed to achieve tablets with the following composition:
• Example 5 Determination of the degree of hygroscopicity of doxylamine succinate and doxylamine polacrilex complex according to the invention:
• the objective of the experiment was to measure the degree of hygroscopicity of the doxylamine polacrilex complex and comparing it with the one of the doxylamine succinate.
• the percentage increase of mass was calculated in order to evaluate the adsorption of water in the samples.
• Table 1 Classification of substances concerning hygroscopicity
• Dynamic Vapour Sorption (DVS) analysis is a technique specifically designed to provide information related to material response to changes in relative humidity and T e C.
• a Q5000 SA DVS equipment from TA Instruments was used for running the experiment.
• a program was configured to run the analysis at 25 e C and 80%RH for 24h.
• a previous program at 60 e C was run until constant weight of the sample in order to begin the analysis with the dried sample.
• ⁇ %weight ( ⁇ ⁇ - ⁇ )/ ⁇ x 100
• P is the initial weight
• P n is the weight measured for the sample.
• Example 6 Drug - excipient compatibility study The objective of the study was to measure the compatibility of doxylamine polacrilex complex with aspartame, a potential sweetener excipient to be used in an oral formulation, and comparing it with the one of doxylamine succinate with the same excipient.
• the amount of active substance present in 180 mg of Doxylamine polacrilex complex is approximately equivalent to the amount of active substance present in 50 mg of Doxylamine succinate.
• Example 7 Powder X-Ray Diffraction (PXRD): (see Fig. 6,7 and 8):

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Biophysics (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Anesthesiology (AREA)
• Molecular Biology (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Publications (1)

Family

ID=44279867

Family Applications (2)

Family Applications Before (1)

Country Status (3)

Families Citing this family (4)

Family Cites Families (2)

• 2011
  • 2011-03-18 EP EP11382072A patent/EP2500016A1/de not_active Withdrawn
• 2012
  • 2012-03-13 WO PCT/EP2012/054364 patent/WO2012126770A1/en active Application Filing
  • 2012-03-13 EP EP12708043A patent/EP2536401A1/de not_active Withdrawn
  • 2012-03-16 AR ARP120100881A patent/AR085431A1/es not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events